



TRIZIVIR

Summary

Trizivir is a combination of three anti-HIV drugs commonly called nukes. Each Trizivir tablet contains 300 mg of abacavir, 150 mg of 3TC and 300 mg of AZT. Common side effects of Trizivir can include unexpected tiredness, diarrhea, nausea, loss of appetite and headache. Trizivir is usually taken at a dose of one tablet twice a day, with or without food.

Note: Up to 8% of the people who take Trizivir may have a serious allergic (“hypersensitivity”) reaction to the abacavir it contains: please see the “Warning” section.

What is Trizivir?

Trizivir is the brand name of three anti-HIV drugs—abacavir (**Ziagen**), **3TC** (lamivudine) and AZT (zidovudine, **Retrovir**)—that are combined together in one tablet. These three drugs belong to a group or class of anti-HIV drugs (antiretrovirals) called nucleoside analogues or “nukes”. Trizivir is used in combination with other anti-HIV drugs to treat, but not cure, HIV/AIDS.

How does Trizivir work?

To explain how Trizivir works, we need to first tell you some information about HIV. When HIV infects a cell, it takes control of that cell. HIV then forces the cell to make many more copies of the virus. In order to make these copies, the cell uses proteins called enzymes. When the activity of these enzymes is reduced or blocked, production of HIV slows or stops.

Trizivir contains abacavir, 3TC and AZT, three drugs that belong to a class of anti-HIV drugs called nukes. These drugs interfere with an

enzyme called reverse transcriptase (RT), which is used by HIV-infected cells to make new viruses. Since abacavir, 3TC and AZT inhibit, or reduce the activity of this enzyme, Trizivir causes HIV-infected cells to slow down or stop producing new viruses.

How do people with HIV/AIDS use Trizivir?

Trizivir is used in combination with another anti-HIV drug from a different class, such as protease inhibitors or non-nukes (NNRTIs). Combinations such as this are called highly active antiretroviral therapy, or HAART. For more information on HAART, see CATIE’s *Practical Guide to HAART for People Living with HIV/AIDS* at www.catie.ca/PG_HAART_e.nsf.

For many people with HIV/AIDS (PHAs), the use of HAART has increased their CD4+ cell counts and decreased the amount of HIV in their blood (viral load). These beneficial effects help to reduce the risk of developing a life-



threatening infection. Neither Trizivir nor any other anti-HIV medication is a cure for HIV/AIDS. It is therefore important that you do the following:

- see your doctor regularly so that he/she monitors your health
- continue to practice safer sex and take other precautions so as not to pass HIV on to other people and protect yourself from different strains of HIV and other germs

Women and Children

Trizivir is not recommended for children because there is no data on its use in this population. Trizivir has not been well studied in pregnant women. The manufacturer suggests that Trizivir only be used in pregnant women if the “benefit to the mother outweighs the risk to the fetus.”

Warnings

1. Hypersensitivity reaction

Up to 8% of PHAs who use Trizivir experience an exaggerated immune reaction against the abacavir component of the combination. **This reaction, called the abacavir hypersensitivity reaction, is very serious and can be fatal.**

Although the hypersensitivity reaction can occur at any time while a person is taking Trizivir, on average it occurs within the first six weeks of use. The reaction can include the following:

- fever
- rash
- gastrointestinal symptoms (including nausea, vomiting, diarrhea, stomach pain)
- general symptoms (including unexpected lack of energy or tiredness, muscle pain, bone pain)
- respiratory symptoms (including cough, shortness of breath, sore throat)

If any of these occur while you are taking Trizivir, you should stop taking this medicine immediately and contact your doctor right away.

To help diagnose hypersensitivity reactions to Trizivir, the manufacturer has set up a 24-hour bilingual, toll-free information service at 1-800-868-8898. A wallet-sized warning card is included in the Trizivir packaging—it should be carried at all times by people taking this drug.

There is now a screening test to help predict whether you are likely to have an abacavir hypersensitivity reaction. See CATIE’s fact sheet *Abacavir Hypersensitivity Screening*, available at www.catie.ca/facts.nsf.

2. Restarting treatment

Trizivir should never be restarted following a hypersensitivity reaction, as a fatal reaction could occur within hours. You should also never take any other drug that contains abacavir (this includes **Ziagen** and **Kivexa**).

This hypersensitivity reaction has even occurred among people who did not have any problems when they first took abacavir-containing drugs, but who then stopped and restarted.

3. Lactic acidosis and hepatic steatosis

Two related conditions, lactic acidosis (a buildup of lactic acid in the blood) and hepatic steatosis (excess fat in the liver), have occurred in some people who have used nukes. These conditions can be serious or fatal. They have mostly been seen in women and people who are overweight or who have been on nukes a long time. Symptoms of lactic acidosis can include the following:

- unexpected tiredness or weakness
- nausea and/or vomiting
- persistent abdominal pain
- diarrhea
- unexpected muscle pain
- feeling cold, especially in the arms and legs
- feeling dizzy or light-headed

If any of these symptoms occur without apparent reason, call your nurse or doctor right away.



Lactic acidosis is rare (less than one case per year for every thousand patients). If you do develop any of these symptoms, it does not necessarily mean you have lactic acidosis, but you should still let your doctor know right away.

4. Hepatitis B

Trizivir contains 3TC, a drug that is used in the treatment of hepatitis B virus infection (HBV). The manufacturer of Trizivir advises that PHAs should get tested for HBV infection before starting HAART. Be aware that discontinuing Trizivir (and therefore 3TC) can have the effect of making HBV infection temporarily worse. If you are co-infected with HBV, talk to your doctor about how best to treat this co-infection.

5. Pancreatitis

Some people taking the two medications found in Trizivir—abacavir and 3TC—have developed a painful inflammation of their pancreas gland. Talk to your doctor right away if these symptoms occur as they may be suggestive of pancreatitis:

- abdominal pain
- nausea
- vomiting
- fever
- anxiety
- unexpected sweating

6. Anemia and bone marrow toxicity

AZT can be toxic to the bone marrow—the soft tissue inside bones where blood cells are made. As a result, AZT can cause anemia (lowered red blood cell levels) and neutropenia (lowered neutrophil or white blood cell counts). In serious cases, this can require blood transfusions, and AZT must be stopped.

People with abnormally low hemoglobin levels or neutrophil counts should not take AZT. People starting AZT should have their blood cell counts monitored closely. If anemia occurs at all, it usually happens within the first four to six weeks after starting AZT. Although it was previously thought to be more common,

a recent large-scale review found that only about 1% to 2% of people taking AZT develop anemia. Estimates of neutropenia range from 1.8% to 8% of people taking AZT.

Side effects

1. General

The general side effects that occur in PHAs taking AZT, 3TC and abacavir separately may also occur in PHAs taking Trizivir. These side effects can include:

- gastrointestinal effects – diarrhea, nausea, vomiting, loss of appetite
- neurologic effects – headache, insomnia
- other effects – unexpected tiredness, muscle pain

Many people find that side effects caused by anti-HIV drugs improve or go away after the first several weeks of treatment.

Less common, but more serious, side effects may include neutropenia (a decrease in the number of white blood cells called neutrophils), and anemia (a decrease in hemoglobin or red blood cells).

In rare cases, the AZT in Trizivir over many years may also cause myopathy, a weakness or loss of muscle mass, especially with long-term use. Some people of colour have experienced darkening of the skin and/or nails while using AZT.

2. Lipodystrophy syndrome

Trizivir contains AZT. Use of AZT may be associated with the loss of the fatty layer under the skin, a process called lipoatrophy. Lipoatrophy is one part of the lipodystrophy syndrome.

The HIV lipodystrophy syndrome is the name given to a range of symptoms that can develop over time when people use HAART regimens. Some features of the lipodystrophy syndrome include:

- loss of fat just under the skin (subcutaneous fat) in the face, arms, and legs



- bulging veins in the arms and/or legs due to the loss of fat under the skin
- increased waist and belly size
- fat pads at the back of the neck (“buffalo hump”) or at the base of the neck (“horse collar”)
- small lumps of fat in the abdomen
- increased breast size (in women)

Together with these physical changes, lab tests of your blood may detect the following:

- increased levels of fatty substances called triglycerides
- increased levels of LDL-cholesterol (low-density lipoprotein) or “bad” cholesterol
- increased levels of sugar (glucose)
- increased levels of the hormone insulin
- decreased sensitivity to insulin (insulin resistance)
- decreased levels of HDL-cholesterol (high-density lipoprotein) or “good” cholesterol

The precise causes of the HIV lipodystrophy syndrome are not clear and are difficult to understand because in some PHAs there may be one or more aspects of the syndrome taking place. For instance, some people may experience fat wasting, others fat gain, and others may experience both fat gain and wasting. What is becoming increasingly clear is that unfavourable changes in the lab readings of glucose, cholesterol, and triglycerides over a period of several years increase the risk of diabetes and cardiovascular disease. So far, however, the many benefits of HAART are much greater than the increased risk of cardiovascular disease or other side effects.

Maintaining a normal weight, eating a healthy diet, exercising regularly, and quitting smoking are all important in helping you to reduce your risk of diabetes, heart disease, and other complications. Regular visits to your doctor for checkups and blood tests are a vital part of staying healthy. If necessary, your doctor can prescribe lipid-lowering therapy.

Researchers are studying the lipodystrophy syndrome to try to discover ways of helping PHAs avoid or reduce this problem. To find out more about options for managing aspects of the lipodystrophy syndrome, see CATIE’s *Practical Guide to HIV Drug Side Effects* at www.catie.ca/sideeffects_e.nsf.

Of all the anti-HIV drugs, 3TC and abacavir (two components of Trizivir) appear to be among the least likely to cause or contribute to lipodystrophy.

Drug interactions

Always consult your doctor and pharmacist about taking any other prescription or non-prescription medication, including herbs, supplements, and street drugs.

Some drugs can interact with the abacavir in Trizivir, increasing or decreasing its levels in your body. Increased drug levels can cause you to experience side effects or make pre-existing side effects worse. On the other hand, if drug levels become too low, HIV can develop resistance and your future treatment options may be reduced.

If you must take a drug that has the potential to interact with your existing medications, your doctor can do the following:

- adjust your dose of either your anti-HIV drugs or other medications
- prescribe different anti-HIV drugs for you

Drug interactions with Trizivir

1. Specific drug interactions: AZT

The following drugs can affect the bone marrow, decreasing the production of white and in some cases, red blood cells. Use of Trizivir with these or other drugs that affect the bone marrow can further reduce levels of these cells. This increases the risk of developing infections and/or anemia:

- dapsone (**Avlosulfon**)



- ganciclovir (**Cytovene**) or valganciclovir (**Valcyte**)
- interferon-alpha and ribavirin
- valproic acid (**Depakene**)

AZT should be used cautiously with these drugs, or not at all.

For some people, methadone increases the blood level of AZT. Aspirin, codeine and morphine can also affect the metabolism of AZT, so use of these drugs should be discussed with your doctor.

AZT should never be combined with d4T.

2. Specific drug interactions: abacavir

In men, the use of alcohol in combination with abacavir causes an increase of abacavir in the blood, which could cause an increase in toxicity. This has not been studied in women.

Abacavir can reduce levels of methadone in the blood, which might require an adjustment to your dose of methadone.

3. Specific drug interactions: 3TC

No significant drug interactions have been reported with 3TC.

Resistance and cross-resistance

Over time, as new copies of HIV are made in the body, the virus changes its structure. These changes are called mutations and can cause HIV to resist the effects of anti-HIV drugs, which means those drugs will no longer work for you. Combining Trizivir with another anti-HIV drug delays the development of drug resistance.

To reduce the risk of developing drug resistance, all anti-HIV drugs should be taken every day exactly as prescribed and directed. If doses are delayed, missed, or not taken as prescribed, levels of abacavir, 3TC or AZT in the blood may fall too low. If this happens, resistant virus can develop. If you find you are

having problems taking your medications as directed, speak to your doctor and nurse about this. They can find ways to help you.

When HIV becomes resistant to one drug in a class, it sometimes becomes resistant to other drugs in that class. This is called cross-resistance. Feel free to talk with your doctor about your current and future treatment options. To help you decide what these future therapies might be, at some point your doctor can have a small sample of your blood analysed using resistance testing. Should HIV in your body become resistant to abacavir, 3TC and/or AZT, your doctor, with the help of resistance testing, can help put together a new treatment regimen for you.

Dosage and formulations

Trizivir is available as tablets, each containing 300 mg abacavir and 150 mg 3TC (lamivudine) and 300 mg AZT. The usual standard adult dose of Trizivir is one tablet twice daily, with or without food. Trizivir is not recommended for people who weigh less than 50 kg (110 lbs). All medications should always be taken as prescribed and directed.

Availability

Trizivir is licensed in Canada for the treatment of HIV infection in adults, in combination with other anti-HIV drugs. Your doctor can tell you more about the availability and coverage of Trizivir in your region. CATIE's online module *Federal, Provincial and Territorial Drug Access Programs* (on CATIE's website at www.catie.ca/eng/Publications/drugaccess/drugaccessIndex.shtml) also contains information about Canadian drug coverage."

Also see CATIE's fact sheets on abacavir, 3TC, AZT and abacavir hypersensitivity screening.



References

Sadiq ST, Pakianathan M. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. *Sexually Transmitted Infections* 2007 Jun;83(3):181-182.

Department of Health and Human Services. *Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents*. 1 December 2007. Available at: aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

GlaxoSmithKline. *Trizivir: Canadian Product Monograph*. 14 March 2007.

Public Health Service Task Force. *Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States*. 2 November 2006.

Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in Western Australian HIV Cohort Study. *Clinical Infectious Diseases* 2006;43(1):99-102.

Edwards MT, Burkle W, Cutrell A, et al. Characterization of anemia in HIV-infected (HIV+) subjects treated with antiretroviral therapy (ART) with and without zidovudine (+/-ZDV) in 54 clinical trials. *Third International AIDS Society Conference on HIV Pathogenesis and Treatment*, Rio de Janeiro, 2005. Abstract TuFo0106.

Jones SP, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. *Journal of Acquired Immune Deficiency Syndromes* 2005;40(5):565-572.

Antoniou T, Gough K, Yoong D and Arbess G. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. *Clinical Infectious Diseases* 2004;38(5):e38-e40.

Maisonneuve C, Igoudjil A, Begriche K, et al. Effects of zidovudine, stavudine, and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. *Antiviral Therapy* 2004;9(5):801-810.

Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue abacavir: the MITOX Extension Study. *AIDS* 2004;18(7):1029-36.

McComsey GA, Ward DJ, Hesselthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. *Clinical Infectious Diseases* 2004;38(2):263-270.

Berenguer J, Padilla B, Estrada V, et al. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. *AIDS* 2002;16(9):1299-1301.

Bart PA, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. *Therapeutic Drug Monitoring* 2001;23(5):553-555.

Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. *Lancet* 2001;358(9290):1322-1327.

Frissen PH, de Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. *AIDS* 2001;15(2):289-292.

Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. *Journal of Biological Chemistry* 2001;276(44):40847-40857.

Loeliger AE, Steel H, McGuirk S, et al. The abacavir hypersensitivity reaction and interruptions in therapy. *AIDS* 2001;15(10):1325.

Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *New England Journal of Medicine* 1994;331(18):1173-1180.

Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *New England Journal of Medicine* 1987;317(4):185-191.

Credits

Author: D Thaczuk, SR Hosein

Design: Renata Lipovitch

2008



Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question.

The Canadian AIDS Treatment Information Exchange (CATIE) in good faith provides information resources to help people living with HIV/AIDS who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

We do not guarantee the accuracy or completeness of any information accessed through or published or provided by CATIE. Users relying on this information do so entirely at their own risk. Neither CATIE nor the Public Health Agency Canada nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. The views expressed herein or in any article or publication accessed or published or provided by CATIE are solely those of the authors and do not reflect the policies or opinions of CATIE or the official policy of the Minister of Health Canada.

Permission to reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by the Canadian AIDS Treatment Information Exchange (CATIE). For more information, contact CATIE at 1.800.263.1638.*

Contact CATIE

by telephone
1.800.263.1638
416.203.7122

by fax
416.203.8284

by e-mail
info@catie.ca

on the Web
<http://www.catie.ca>

by mail
505-555 Richmond Street West
Box 1104
Toronto ON M5V 3B1
Canada



Funding has been provided by the Public Health Agency of Canada.

